(Q42646492)

4 November 2017

title

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel (English)

1 reference

4 November 2017

1 reference

1 reference

1 reference

3

1 reference

4 November 2017

David S Small

1

1 reference

4 November 2017

Nagy A Farid

2

1 reference

4 November 2017

Govinda J Weerakkody

4

1 reference

4 November 2017

Ying G Li

5

1 reference

4 November 2017

John T Brandt

6

1 reference

4 November 2017

Daniel E Salazar

7

1 reference

4 November 2017

Kenneth J Winters

8

1 reference

4 November 2017

language of work or name

1 reference

26 February 2008

1 reference

The Journal of Clinical Pharmacology

4 November 2017

published in

1 reference

4 November 2017

volume

48

1 reference

4 November 2017

issue

4

1 reference

4 November 2017

page(s)

475-484

1 reference

Atherothrombosis and high-risk plaque: part I: evolving concepts

4 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Platelets in atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Regulation of platelet functions by P2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

The disposition of prasugrel, a novel thienopyridine, in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Greater inhibition of platelet aggregation and reduced response variability with prasugrel versus clopidogrel: an integrated analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0091270008315310

21 January 2018

Identifiers

DOI

10.1177/0091270008315310

1 reference

4 November 2017

1 reference